Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen

Author： Serdjebi Cindy   Seitz Jean-François   Ciccolini Joseph   Duluc Muriel   Norguet Emmanuelle   Fina Frédéric   Lacarelle Bruno   Ouafik L'Houcine   Dahan Laetitia  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.9, 2013-07, pp. : 1047-1051

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer

By Banu Eugeniu  

Drugs & Aging, Vol. 24, Iss. 10, 2007-01 ,pp. : 865-879

Adis International

Access to resources Recommend Favorite

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine

By Woo Hye In   Kim Ka-Kyung   Choi Hangseok   Kim Seonwoo   Jang Kee-Taek   Yi Jun Ho   Park Young Suk   Park Joon Oh   Lee Soo-Youn  

Pharmacogenomics, Vol. 13, Iss. 9, 2012-07 ,pp. : 1023-1035

Future Medicine

Access to resources Recommend Favorite

Gemcitabine-based doublets are more effective than gemcitabine alone for advanced and metastatic pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 7, 2015-08 ,pp. : 386-395

John Wiley & Sons Inc

Access to resources Recommend Favorite

Erlotinib + gemcitabine of no value in pancreatic cancer

By  

Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite